Supplementary Data from Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation

Supplemental Figures and Tables. Figure S1 - Immunoblotting characterization of GMB-101 and GMB-475. Figure S2 - Validation of degradation and compound toxicity via comparison of GMB-475 and GMB-651. Figure S3 - Combinations of ATP competitive TKIs with PROTAC. Figure S4 - Schematic of scaffolding roles, VHL ligand and imatinib controls for VHL and pGAB2. Figure S5 - Patient sample sorting workflow and additional patient samples. Table S2 - Patient characteristics for primary samples